Vertex Pharmaceuticals Inc (VRTX) — Capital Reinvestment Ratio

Latest as of March 2026: 0.09x

Vertex Pharmaceuticals Inc (VRTX) has a Capital Reinvestment Ratio of 0.09x as of March 2026, meaning it reinvests 0% of its operating cash flow ($1.43 Billion) in capital expenditures ($133.40 Million). See Vertex Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.09x
Capex / Operating Cash Flow

Operating Cash Flow

$1.43 Billion
USD

Capital Expenditures

$133.40 Million
USD

Data as of

Mar 2026
Most recent filing

Vertex Pharmaceuticals Inc Capital Reinvestment Ratio (1993–2025)

This chart tracks Vertex Pharmaceuticals Inc's Capital Reinvestment Ratio across 12 annual periods. Check how aggressively does Vertex Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Vertex Pharmaceuticals Inc (1993–2025)

Year-by-year Capital Reinvestment Ratio for Vertex Pharmaceuticals Inc from 1993 to 2025. For live market cap and broader valuation context, see VRTX market cap.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.12x $3.63 Billion $437.60 Million ▲ +65.0%
2023 0.07x $3.54 Billion $258.40 Million ▲ +47.4%
2022 0.05x $4.13 Billion $204.70 Million ▼ -44.2%
2021 0.09x $2.64 Billion $235.00 Million ▲ +11.3%
2020 0.08x $3.25 Billion $259.80 Million ▲ +66.1%
2019 0.05x $1.57 Billion $75.45 Million ▼ -36.1%
2018 0.08x $1.27 Billion $95.52 Million ▼ -75.5%
2017 0.31x $844.94 Million $259.42 Million ▲ +28.2%
2016 0.24x $236.10 Million $56.56 Million ▼ -9.8%
2012 0.27x $267.84 Million $71.14 Million ▼ -59.6%
2011 0.66x $143.74 Million $94.59 Million ▲ +214.4%
1993 0.21x $8.60 Million $1.80 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow